Zacks Investment Research upgraded shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) from a hold rating to a buy rating in a research note released on Tuesday. They currently have $5.50 price target on the biopharmaceutical company’s stock.

According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “

PRQR has been the subject of a number of other research reports. HC Wainwright restated a buy rating and issued a $40.00 price objective on shares of ProQR Therapeutics N.V. in a research report on Tuesday, June 20th. ValuEngine upgraded ProQR Therapeutics N.V. from a strong sell rating to a sell rating in a research report on Friday, September 1st. Chardan Capital reissued a neutral rating on shares of ProQR Therapeutics N.V. in a research note on Sunday, September 17th. JMP Securities increased their target price on ProQR Therapeutics N.V. from $14.00 to $20.00 and gave the stock an outperform rating in a research note on Tuesday, September 26th. Finally, Leerink Swann reissued an outperform rating and issued a $12.00 price target (up from $10.00) on shares of ProQR Therapeutics N.V. in a report on Tuesday, September 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company has an average rating of Buy and an average target price of $16.40.

ProQR Therapeutics N.V. (PRQR) traded up 2.717% during trading on Tuesday, reaching $4.725. 53,887 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $5.20 and a 200 day moving average price of $5.05. The firm’s market capitalization is $113.90 million. ProQR Therapeutics N.V. has a 52 week low of $3.65 and a 52 week high of $8.70.

COPYRIGHT VIOLATION WARNING: This article was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/10/04/proqr-therapeutics-n-v-prqr-upgraded-to-buy-by-zacks-investment-research.html.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC purchased a new position in ProQR Therapeutics N.V. in the second quarter valued at about $2,028,000. Artal Group S.A. lifted its position in shares of ProQR Therapeutics N.V. by 25.0% during the 2nd quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock valued at $2,600,000 after acquiring an additional 100,000 shares during the period. Finally, Redmile Group LLC boosted its stake in shares of ProQR Therapeutics N.V. by 2.8% during the 2nd quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock worth $8,301,000 after acquiring an additional 43,050 shares in the last quarter. Institutional investors own 35.93% of the company’s stock.

ProQR Therapeutics N.V. Company Profile

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

Receive News & Stock Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related stocks with our FREE daily email newsletter.